Drug Trial Radar · NCT02681172
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Oct 2015
Primary completion
Sep 2016
Study completion Nov 2016
Sponsor
- Lead sponsor
- Lantheus Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Health services research
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 4 study will explore, in the context of the present French clinical practice, the impact of florbetaben 18F (FBB) in patients evaluated for AD who require a biomarker for etiologic determination of the cognitive and functional impairment, but in whom: 1. lumbar puncture was not feasible for medical conditions 2. results of cerebrospinal fluid (CSF) analysis were considered ambiguous by treating physicians 3. lumbar puncture (LP) was refused by the patient
Conditions
- Alzheimer's Disease (AD)
Interventions
Neuraceq (florbetaben 18F)Drug
Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
PETProcedure
A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Change of Diagnosis Comparing Pre- and Post-scan OutcomesTime frame: Visit 1 (baseline evaluation) and Visit 3 (up to 6 months later)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Coordinating center (Hôpital de La Timone) and 18 associated centers in France
Marseille, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.